• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鳞状细胞癌通过诱导共表达PD-1和LAG-3抑制性受体的CD8+ T细胞的慢性激活和耗竭来逃避免疫监视。

Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.

作者信息

Mishra Ameet K, Kadoishi Tanya, Wang Xiaoguang, Driver Emily, Chen Zhangguo, Wang Xiao-Jing, Wang Jing H

机构信息

Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.

Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.

出版信息

Oncotarget. 2016 Dec 6;7(49):81341-81356. doi: 10.18632/oncotarget.13228.

DOI:10.18632/oncotarget.13228
PMID:27835902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5340255/
Abstract

Squamous cell carcinoma (SCC) is the second commonest type of skin cancer. Moreover, about 90% of head and neck cancers are SCCs. SCCs develop at a significantly higher rate under chronic immunosuppressive conditions, implicating a role of immune surveillance in controlling SCCs. It remains largely unknown how SCCs evade immune recognition. Here, we established a mouse model by injecting tumor cells derived from primary SCCs harboring KrasG12D mutation and Smad4 deletion into wild-type (wt) or CD8-/- recipients. We found comparable tumor growth between wt and CD8-/- recipients, indicating a complete escape of CD8+ T cell-mediated anti-tumor responses by these SCCs. Mechanistically, CD8+ T cells apparently were not defective in infiltrating tumors given their relatively increased percentage among tumor infiltrating lymphocytes (TILs). CD8+ TILs exhibited phenotypes of chronic activation and exhaustion, including overexpression of activation markers, co-expression of programmed cell death 1 (PD-1) and lymphocyte activation gene-3 (LAG-3), as well as TCRβ downregulation. Among CD4+ TILs, T regulatory cells (Tregs) were preferentially expanded. Contradictory to prior findings in melanoma, Treg expansion was independent of CD8+ T cells in our SCC model. Unexpectedly, CD8+ T cells were required for promoting NK cell infiltration within SCCs. Furthermore, we uncovered AKT-dependent lymphocyte-induced PD-L1 upregulation on SCCs, which was contributed greatly by combinatorial effects of CD8+ T and NK cells. Lastly, dual blockade of PD-1 and LAG-3 inhibited the tumor growth of SCCs. Thus, our findings identify novel immune evasion mechanisms of SCCs and suggest that immunosuppressive mechanisms operate in a cancer-type specific and context-dependent manner.

摘要

鳞状细胞癌(SCC)是第二常见的皮肤癌类型。此外,约90%的头颈癌为SCC。在慢性免疫抑制条件下,SCC的发生速率显著更高,这表明免疫监视在控制SCC中发挥作用。SCC如何逃避免疫识别在很大程度上仍然未知。在此,我们通过将携带KrasG12D突变和Smad4缺失的原发性SCC来源的肿瘤细胞注射到野生型(wt)或CD8基因敲除(CD8-/-)受体小鼠中,建立了一个小鼠模型。我们发现wt受体小鼠和CD8-/-受体小鼠之间的肿瘤生长情况相当,这表明这些SCC能够完全逃避CD8+ T细胞介导的抗肿瘤反应。从机制上讲,鉴于CD8+ T细胞在肿瘤浸润淋巴细胞(TILs)中的百分比相对增加,其浸润肿瘤的能力显然没有缺陷。CD8+ TILs表现出慢性激活和耗竭的表型,包括激活标志物的过度表达、程序性细胞死亡1(PD-1)和淋巴细胞激活基因-3(LAG-3)的共表达以及TCRβ下调。在CD4+ TILs中,调节性T细胞(Tregs)优先扩增。与先前在黑色素瘤中的发现相反,在我们的SCC模型中,Treg扩增独立于CD8+ T细胞。出乎意料的是,促进NK细胞浸润SCC需要CD8+ T细胞。此外,我们发现SCC上存在AKT依赖性的淋巴细胞诱导的PD-L-1上调,这在很大程度上是由CD8+ T细胞和NK细胞的联合作用促成的。最后,双重阻断PD-1和LAG-3可抑制SCC的肿瘤生长。因此,我们的研究结果确定了SCC新的免疫逃逸机制,并表明免疫抑制机制以癌症类型特异性和背景依赖性方式发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/7689f48cdeaf/oncotarget-07-81341-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/8b50a0d347d0/oncotarget-07-81341-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/f5e4e35e9073/oncotarget-07-81341-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/78b0ef9ff27a/oncotarget-07-81341-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/bd7b5756618b/oncotarget-07-81341-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/099ef08309b2/oncotarget-07-81341-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/14b2baba36b5/oncotarget-07-81341-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/2a64c27ef954/oncotarget-07-81341-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/7689f48cdeaf/oncotarget-07-81341-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/8b50a0d347d0/oncotarget-07-81341-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/f5e4e35e9073/oncotarget-07-81341-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/78b0ef9ff27a/oncotarget-07-81341-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/bd7b5756618b/oncotarget-07-81341-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/099ef08309b2/oncotarget-07-81341-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/14b2baba36b5/oncotarget-07-81341-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/2a64c27ef954/oncotarget-07-81341-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33de/5340255/7689f48cdeaf/oncotarget-07-81341-g008.jpg

相似文献

1
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.鳞状细胞癌通过诱导共表达PD-1和LAG-3抑制性受体的CD8+ T细胞的慢性激活和耗竭来逃避免疫监视。
Oncotarget. 2016 Dec 6;7(49):81341-81356. doi: 10.18632/oncotarget.13228.
2
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
3
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.α-PD-1 治疗可提高 Treg/Th 平衡,并增加肿瘤细胞 pSmad3,而 α-TGFβ 抗体可靶向这两者,以促进鳞状细胞癌的持久排斥和免疫。
J Immunother Cancer. 2019 Mar 4;7(1):62. doi: 10.1186/s40425-018-0493-9.
4
Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.浅表血管肉瘤中的免疫检查点标志物:PD-L1、PD-1、CD8、LAG-3 和肿瘤浸润淋巴细胞。
Am J Dermatopathol. 2021 Aug 1;43(8):556-559. doi: 10.1097/DAD.0000000000001843.
5
Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8 T Cells is Determined by Their Differentiation Status in Glioblastoma.免疫检查点抑制剂诱导的胶质母细胞瘤中浸润 CD8 T 细胞的再激活取决于其分化状态。
Clin Cancer Res. 2019 Apr 15;25(8):2549-2559. doi: 10.1158/1078-0432.CCR-18-2564. Epub 2019 Jan 18.
6
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.HIV 状态与肛门鳞状细胞癌局部免疫反应的关系:对免疫治疗的启示。
JAMA Oncol. 2017 Jul 1;3(7):974-978. doi: 10.1001/jamaoncol.2017.0115.
7
TOX-expressing terminally exhausted tumor-infiltrating CD8 T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer.在膀胱癌中,共阻断 PD-1 和 TIGIT 可重新激活表达 TOX 的终末耗竭肿瘤浸润 CD8 T 细胞。
Cancer Lett. 2021 Feb 28;499:137-147. doi: 10.1016/j.canlet.2020.11.035. Epub 2020 Nov 27.
8
Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.脓毒症引起的免疫麻痹状态是由 CD8 T 细胞介导的抗肿瘤免疫作用减弱定义的。
J Immunol. 2019 Aug 1;203(3):725-735. doi: 10.4049/jimmunol.1900435. Epub 2019 Jun 12.
9
CD103CD8 T Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17.CD103CD8 T 细胞在抗 PD-1 应答的肺癌患者的肿瘤中积累,并且富含 Tc17 的肿瘤反应性淋巴细胞。
Cell Rep Med. 2020 Oct 20;1(7):100127. doi: 10.1016/j.xcrm.2020.100127.
10
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.肿瘤浸润性 NY-ESO-1 特异性 CD8+ T 细胞在人卵巢癌中受 LAG-3 和 PD-1 的负调控。
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.

引用本文的文献

1
The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.芳烃受体通过JAK/STAT途径调控肺腺癌中IFN-γ诱导的免疫检查点PD-L1和IDO。
J Immunol. 2025 Mar 3. doi: 10.1093/jimmun/vkae023.
2
Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas.探索 EGFR 突变型肺腺癌中小细胞转化的机制并构建模型。
Signal Transduct Target Ther. 2024 Oct 2;9(1):261. doi: 10.1038/s41392-024-01981-3.
3
The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma.

本文引用的文献

1
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.用于癌症治疗的PD-L1(B7-H1)和PD-1通路阻断:作用机制、反应生物标志物及联合应用
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
2
Antitumour actions of interferons: implications for cancer therapy.干扰素的抗肿瘤作用:对癌症治疗的启示。
Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14.
3
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
芳烃受体通过JAK/STAT途径调控肺腺癌中IFNγ诱导的免疫检查点PD-L1和IDO。
bioRxiv. 2024 Aug 13:2024.08.12.607602. doi: 10.1101/2024.08.12.607602.
4
Pro-inflammatory responses after peptide-based cancer immunotherapy.基于肽的癌症免疫治疗后的促炎反应。
Heliyon. 2024 May 31;10(11):e32249. doi: 10.1016/j.heliyon.2024.e32249. eCollection 2024 Jun 15.
5
Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.口腔癌前病变:新治疗方法的最新进展。
Curr Oncol Rep. 2024 Sep;26(9):1047-1056. doi: 10.1007/s11912-024-01562-1. Epub 2024 Jun 12.
6
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity.颗粒酶 F:嵌合抗原受体 T 细胞介导的细胞毒性的耗竭标志物和调节剂。
J Immunol. 2024 Apr 15;212(8):1381-1391. doi: 10.4049/jimmunol.2300334.
7
Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.头颈癌中的免疫逃逸策略:逃避、抵抗、抑制、招募。
Cancers (Basel). 2024 Jan 11;16(2):312. doi: 10.3390/cancers16020312.
8
Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.免疫检查点抑制剂和适体的癌症免疫治疗:概述。
Med Oncol. 2023 Dec 29;41(1):40. doi: 10.1007/s12032-023-02267-4.
9
Exploring animal models in oral cancer research and clinical intervention: A critical review.探讨口腔癌研究和临床干预中的动物模型:批判性评价。
Vet Med Sci. 2023 Jul;9(4):1833-1847. doi: 10.1002/vms3.1161. Epub 2023 May 17.
10
Global research trends in immunotherapy for head and neck neoplasms: A scientometric study.头颈部肿瘤免疫治疗的全球研究趋势:一项科学计量学研究。
Heliyon. 2023 Apr 13;9(4):e15309. doi: 10.1016/j.heliyon.2023.e15309. eCollection 2023 Apr.
基于痘病毒的主动免疫疗法联合PD-1和LAG-3双重免疫检查点抑制可克服代偿性免疫调节,使小鼠肿瘤完全消退。
PLoS One. 2016 Feb 24;11(2):e0150084. doi: 10.1371/journal.pone.0150084. eCollection 2016.
4
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.头颈部鳞状细胞癌患者的肿瘤浸润淋巴细胞与生存情况
Head Neck. 2016 Jul;38(7):1074-84. doi: 10.1002/hed.24406. Epub 2016 Feb 16.
5
Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.头颈癌中的抗肿瘤免疫:理解证据、肿瘤逃逸机制及免疫治疗方法
Cancers (Basel). 2015 Dec 9;7(4):2397-414. doi: 10.3390/cancers7040900.
6
Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.肿瘤浸润性B细胞与T细胞之间的相互作用控制着肝细胞癌的进展。
Gut. 2017 Feb;66(2):342-351. doi: 10.1136/gutjnl-2015-310814. Epub 2015 Dec 15.
7
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.致癌激活 AKT-mTOR 通路对非小细胞肺癌 PD-L1 表达的调控。
Cancer Res. 2016 Jan 15;76(2):227-38. doi: 10.1158/0008-5472.CAN-14-3362. Epub 2015 Dec 4.
8
Immunology and Immunotherapy of Head and Neck Cancer.头颈部癌症的免疫学与免疫治疗
J Clin Oncol. 2015 Oct 10;33(29):3293-304. doi: 10.1200/JCO.2015.61.1509. Epub 2015 Sep 8.
9
Clinical Development of Immune Checkpoint Inhibitors.免疫检查点抑制剂的临床开发。
Biomed Res Int. 2015;2015:605478. doi: 10.1155/2015/605478. Epub 2015 Jun 16.
10
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.免疫检查点阻断开辟了一条具有强大临床疗效的癌症免疫治疗途径。
Cancer Sci. 2015 Aug;106(8):945-50. doi: 10.1111/cas.12695. Epub 2015 Jul 2.